Bactiguard Holding AB (DE:5JE)
FRANKFURT:5JE
5JE Stock Chart & Stats
€1.62
-€0.03(-0.91%)
At close: 4:00 PM EST
€1.62
-€0.03(-0.91%)
Day’s Range― - ―
52-Week Range€1.23 - €3.31
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€51.58M
Enterprise Value€669.14M
Total Cash (Recent Filing)€35.34M
Total Debt (Recent Filing)€161.30M
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Jul 14, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding31,043,884
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.20
Price to Book (P/B)2.21
Price to Sales (P/S)3.23
P/FCF Ratio-96.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)€20.09M
Bulls Say, Bears Say
Bulls Say
BIP Licensing ModelLicensing the BIP noble‑metal coating lets Bactiguard monetize proprietary infection‑prevention IP without heavy manufacturing. This asset‑light model supports scalable, royalty-based revenue, lower capital intensity, and enduring partner distribution that can deliver steady long-term cash flows.
Manageable LeverageBalance-sheet metrics show manageable leverage and solid equity relative to total assets, providing financial flexibility to fund commercialization and R&D. Lower relative debt reduces refinancing pressure and supports a more durable runway compared with highly leveraged peers.
Underlying Operating Cash/EBITDAA positive EBITDA margin and slightly positive operating cash flow in the TTM indicate underlying operational capability. If sustained, these metrics support reinvestment and a credible pathway to profitability even as non‑cash items and financing costs are addressed over the medium term.
Bears Say
Ongoing Net LossesPersistent negative EBIT and net income limit internal capital generation and shareholder returns. Continued unprofitability requires external funding or material margin improvement to avoid dilution, constraining long-term strategic flexibility and investor confidence in sustainable earnings.
Declining Revenue TrendA TTM revenue decline extends a choppy top‑line trend and suggests slower adoption or uneven partner rollouts. Declining revenues make it harder to achieve scale-driven cost leverage and royalty growth, raising execution risk for the licensing and product sales model over the medium term.
Negative And Inconsistent FCFFree cash flow turned negative and has worsened versus the prior year, while cash generation has been inconsistent. Recurring negative FCF increases reliance on external financing, limits reinvestment capacity, and elevates the risk that strategic initiatives cannot be fully funded without diluting stakeholders.
Bactiguard Holding AB News
5JE FAQ
What was Bactiguard Holding AB’s price range in the past 12 months?
Bactiguard Holding AB lowest stock price was €1.23 and its highest was €3.31 in the past 12 months.
What is Bactiguard Holding AB’s market cap?
Bactiguard Holding AB’s market cap is €51.58M.
When is Bactiguard Holding AB’s upcoming earnings report date?
Bactiguard Holding AB’s upcoming earnings report date is Jul 14, 2026 which is in 34 days.
How were Bactiguard Holding AB’s earnings last quarter?
Bactiguard Holding AB released its earnings results on Apr 23, 2026. The company reported -€0.015 earnings per share for the quarter, missing the consensus estimate of -€0.007 by -€0.007.
Is Bactiguard Holding AB overvalued?
According to Wall Street analysts Bactiguard Holding AB’s price is currently Overvalued.
Does Bactiguard Holding AB pay dividends?
Bactiguard Holding AB does not currently pay dividends.
What is Bactiguard Holding AB’s EPS estimate?
Bactiguard Holding AB’s EPS estimate is -0.02.
How many shares outstanding does Bactiguard Holding AB have?
Bactiguard Holding AB has 31,043,884 shares outstanding.
What happened to Bactiguard Holding AB’s price movement after its last earnings report?
Bactiguard Holding AB reported an EPS of -€0.015 in its last earnings report, missing expectations of -€0.007. Following the earnings report the stock price went down -1.01%.
Which hedge fund is a major shareholder of Bactiguard Holding AB?
Currently, no hedge funds are holding shares in DE:5JE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bactiguard Holding AB
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs) and reduce the global dependency on antibiotics. The core of Bactiguard's product line, known as Bactiguard Infection Protection (BIP), encompasses a range of coated medical devices. This includes various urinary catheters, such as the BIP Foley Catheter and the temperature-sensing BIP Foley TempSensor, all engineered to inhibit microbial adhesion and prevent urinary tract infections. Similarly, the BIP Central Venous Catheter and BIP Endotracheal Tube (with the BIP Endotracheal Tube Evac variant offering subglottic secretion drainage) work to reduce the risk of bloodstream and respiratory tract infections by minimizing biofilm formation. Beyond its BIP portfolio, the company offers a diverse array of other products, including Hydrocyn aqua advanced wound care for cleaning and debriding acute, chronic, and infected wounds, as well as general Bactiguard Wound Care items. It also provides a comprehensive selection of surgical sutures (natural absorbable, synthetic absorbable, non-absorbable, and specialty types), VigiMesh for hernia repair, and Hydrocyn aqua advanced disinfectant for sanitizing skin and surfaces. Additionally, Bactiguard supplies specialized orthopedic trauma implants featuring infection prevention technology under the ZNN Bactiguard brand, and the Aniocyn line of wound and skin care products for various pets. Bactiguard Holding AB (publ) was established in 2005 and maintains its headquarters in Tullinge, Sweden.